A 21-year-old pregnant woman carrying twins developed severe breathing problems within 48 hours of receiving atosiban, a medication commonly used to delay preterm labor. Doctors initially ruled out heart disease, blood clots, and infection before concluding the drug itself was responsible. The case, published in August 2026, adds to a small but growing body of evidence that atosiban can trigger a life-threatening condition called non-cardiogenic pulmonary edema, where fluid accumulates in the lungs despite normal heart function.

What Is Atosiban and Why Is It Used in Pregnancy?

Atosiban is an oxytocin receptor antagonist, meaning it blocks the hormonal signals that trigger uterine contractions. It is widely prescribed in Europe and other regions to stop or delay preterm labor, giving doctors time to administer steroids that help fetal lungs mature and allowing transfer to specialized perinatal centers when necessary. Preterm labor affects approximately 5% to 18% of pregnancies worldwide, depending on the population studied.

The drug has earned a reputation as one of the safest tocolytic agents available. Large randomized controlled trials have shown significantly fewer maternal cardiovascular side effects with atosiban compared to older medications like beta-agonists, which can cause dangerous heart rhythm problems and fluid buildup in the lungs.

How Rare Is This Lung Complication?

Non-cardiogenic pulmonary edema associated with atosiban is exceptionally uncommon. A systematic review identified only seven published cases in the medical literature before this new case report, most occurring in women carrying multiple pregnancies who also received antenatal corticosteroids. Despite atosiban's widespread use globally, clinicians remain largely unaware of this potential adverse effect, and the underlying mechanisms remain poorly understood.

In contrast, pulmonary edema linked to other tocolytic medications, particularly beta-agonists and calcium channel blockers, has been documented much more frequently. The rarity of atosiban-related cases may reflect both the drug's genuine safety profile and underreporting of complications.

What Happened in This Case?

The patient was a first-time mother carrying dichorionic diamniotic twins (two separate placentas and amniotic sacs) conceived through in vitro fertilization. She was admitted at 24 weeks and four days of gestation with threatened preterm labor and preterm premature rupture of membranes. Her medical history included a splenectomy in childhood, previous endometriosis surgery, and self-reported asthma. During pregnancy, she developed gestational diabetes mellitus, which was managed with diet and metformin without requiring insulin.

Upon admission, she received standard treatment: atosiban as a 6.75 milligram intravenous bolus followed by continuous infusion, magnesium sulfate for fetal brain protection, antibiotics for infection prevention, and betamethasone to accelerate fetal lung maturation. Approximately 48 hours after atosiban therapy began, she developed progressive shortness of breath and low blood oxygen levels requiring supplemental oxygen.

How Did Doctors Identify the Drug as the Culprit?

The diagnostic process was thorough and systematic. Physicians performed extensive testing to rule out other causes of acute lung injury:

• Cardiac evaluation: Transthoracic echocardiography showed normal heart function with preserved left ventricular systolic function and no signs of elevated filling pressures, ruling out cardiogenic pulmonary edema
• Infection screening: Viral polymerase chain reaction (PCR) testing for influenza and SARS-CoV-2 came back negative, eliminating infectious causes
• Blood clot assessment: Pulmonary perfusion scintigraphy showed no evidence of pulmonary embolism, a common cause of acute respiratory distress
• Imaging findings: Chest radiography revealed bilateral diffuse alveolar-interstitial infiltrates consistent with non-cardiogenic pulmonary edema

The temporal relationship between atosiban initiation and symptom onset, combined with the absence of alternative explanations, pointed directly to the medication. By day three, with respiratory failure worsening despite oxygen support reaching 60% concentration, the patient was transferred to intensive care. Atosiban was immediately discontinued, and she received loop diuretics and respiratory support. Rapid clinical improvement followed the drug's discontinuation, strongly supporting a drug-related cause.

Why Does This Matter for Pregnant Women?

While atosiban-associated pulmonary edema remains extraordinarily rare, this case highlights an important clinical lesson: even medications with excellent safety profiles can cause unexpected complications in specific patient populations. Women carrying multiple pregnancies who receive both atosiban and antenatal corticosteroids appear to face elevated risk, though the exact mechanism remains unclear.

Healthcare providers need heightened awareness of this potential complication, particularly when caring for pregnant patients on atosiban who develop unexplained shortness of breath or low oxygen levels. Early recognition and discontinuation of the drug can be lifesaving, as demonstrated in this case.

Steps for Healthcare Providers to Monitor Atosiban Safety

• Baseline assessment: Document respiratory status, oxygen saturation, and any history of lung disease before starting atosiban therapy
• Continuous monitoring: Assess oxygen levels, breathing difficulty, and lung sounds regularly during atosiban infusion, especially in women with multiple pregnancies
• Rapid investigation: When dyspnea or hypoxemia develops during tocolytic therapy, perform systematic diagnostic workup to exclude cardiac, infectious, and thromboembolic causes before attributing symptoms to other pregnancy complications
• Medication review: Consider discontinuing atosiban if non-cardiogenic pulmonary edema is suspected, as rapid improvement typically follows drug withdrawal

The case underscores that even well-tolerated medications require vigilant clinical oversight. As atosiban continues to be prescribed worldwide for preterm labor prevention, clinicians should maintain awareness of this rare but serious adverse effect and communicate the warning signs to pregnant patients and their families.